Phase 1 Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients

PURPOSE: Sirolimus is the eponymous inhibitor of the mammalian target of rapamycin (mTOR); however, only its analogues have been approved as cancer therapies. Nevertheless, sirolimus is readily available, has been well-studied in organ transplant patients, and demonstrates efficacy in several precli...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Cohen, Ezra EW, Wu, Kehua, Hartford, Christine, Kocherginsky, Masha, Eaton, Kimberly Napoli, Zha, Yuanyuan, Nallari, Anitha, Maitland, Michael L, Fox-Kay, Kammi, Moshier, Kristin, House, Larry, Ramirez, Jacqueline, Undevia, Samir D, Fleming, Gini F, Gajewski, Thomas F, Ratain, Mark J
Médium: Artigo
Jazyk:Inglês
Vydáno: 2012
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4410974/
https://ncbi.nlm.nih.gov/pubmed/22872575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-0110
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky